GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Level Bio AB (XSAT:LEVBIO) » Definitions » Debt-to-Revenue

Level Bio AB (XSAT:LEVBIO) Debt-to-Revenue : 0.00 (As of Mar. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Level Bio AB Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Level Bio AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Level Bio AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Level Bio AB's annualized Revenue for the quarter that ended in Mar. 2024 was kr22.02 Mil. Level Bio AB's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.00.


Level Bio AB Debt-to-Revenue Historical Data

The historical data trend for Level Bio AB's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Level Bio AB Debt-to-Revenue Chart

Level Bio AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.14 0.05 0.02 0.02 0.04

Level Bio AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.05 -

Competitive Comparison of Level Bio AB's Debt-to-Revenue

For the Diagnostics & Research subindustry, Level Bio AB's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Level Bio AB's Debt-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Level Bio AB's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Level Bio AB's Debt-to-Revenue falls into.



Level Bio AB Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Level Bio AB's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.107 + 0) / 26.096
=0.04

Level Bio AB's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 0) / 22.016
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Level Bio AB Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Level Bio AB's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Level Bio AB (XSAT:LEVBIO) Business Description

Traded in Other Exchanges
Address
Vastra Finnbodavagen 4B, Nacka, Stockholm, SWE, 131 30
AlphaHelix Molecular Diagnostics AB develops, manufactures, and markets products for DNA-identification and quantitation in molecular diagnostics and life science research. Its product inlcude Rob, BugScreener MRSA, and aAmp. The company applications inlcude Diagnostics, PCR and Liquid handling.

Level Bio AB (XSAT:LEVBIO) Headlines

No Headlines